ClinVar Miner

Submissions for variant NM_000527.5(LDLR):c.1057G>A (p.Glu353Lys)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
LDLR-LOVD, British Heart Foundation RCV000237927 SCV000295172 uncertain significance Hypercholesterolemia, familial, 1 2016-03-25 criteria provided, single submitter literature only
Laboratory of Genetics and Molecular Cardiology, University of São Paulo RCV000237927 SCV000588545 uncertain significance Hypercholesterolemia, familial, 1 2016-03-01 criteria provided, single submitter research
Invitae RCV000775052 SCV000821458 uncertain significance Familial hypercholesterolemia 2022-09-13 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 353 of the LDLR protein (p.Glu353Lys). This variant is present in population databases (rs370471092, gnomAD 0.03%). This missense change has been observed in individual(s) with familial hypercholesterolemia and myocardial infarction (PMID: 11810272, 15823288, 20506408, 25647241, 27828139, 27878139, 30971288). This variant is also known as p.Glu332Lys. ClinVar contains an entry for this variant (Variation ID: 161275). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LDLR protein function. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on LDLR function (PMID: 25647241). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Color Diagnostics, LLC DBA Color Health RCV000775052 SCV000909152 uncertain significance Familial hypercholesterolemia 2023-11-16 criteria provided, single submitter clinical testing This missense variant replaces glutamic acid with lysine at codon 353 of the LDLR protein. This variant is also known as p.Glu332Lys in the mature protein. Computational prediction tools indicate that this variant's impact on protein structure and function is inconclusive. A functional study using transfected HeLa cells has shown inconclusive results regarding this variant's impact on LDLR expression (PMID: 25647241). This variant has been reported in four individuals affected with familial hypercholesterolemia (PMID: 11810272, 15823288, 20506408, 33994402, 34998859), as well as in one individual affected with premature myocardial infarction (PMID: 30971288). This variant has been identified in 16/281978 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002399518 SCV002713861 uncertain significance Cardiovascular phenotype 2022-10-26 criteria provided, single submitter clinical testing The p.E353K variant (also known as c.1057G>A), located in coding exon 7 of the LDLR gene, results from a G to A substitution at nucleotide position 1057. The glutamic acid at codon 353 is replaced by lysine, an amino acid with similar properties. This alteration has been reported in individuals with familial hypercholesterolemia (FH) and myocardial infarction (Fouchier SW et al. Hum Genet, 2001 Dec;109:602-15; Damgaard D et al. Atherosclerosis, 2005 May;180:155-60; Huijgen R et al. Hum Mutat, 2010 Jun;31:752-60; Thormaehlen AS et al. PLoS Genet, 2015 Feb;11:e1004855; Chiou KR et al. J Clin Lipidol 2017 Jan;11:386-393.e6; Dron JS et al. BMC Med Genomics, 2020 02;13:23). This alteration has also been reported in exome cohorts (Dorschner MO et al. Am J Hum Genet, 2013 Oct;93:631-40; Do R et al. Nature, 2015 Feb;518:102-6). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Fulgent Genetics, Fulgent Genetics RCV000237927 SCV002784200 uncertain significance Hypercholesterolemia, familial, 1 2021-11-21 criteria provided, single submitter clinical testing
Dept. of Genetics and Pharmacogenomics, Merck Research Labs RCV000161978 SCV000189553 not provided not provided no assertion provided in vitro
CSER _CC_NCGL, University of Washington RCV002051668 SCV000190295 uncertain significance Hypercholesterolemia 2014-06-01 no assertion criteria provided research
Laboratorium voor Moleculaire Diagnostiek Experimentele Vasculaire Geneeskunde, Academisch Medisch Centrum RCV000237927 SCV000606304 pathogenic Hypercholesterolemia, familial, 1 no assertion criteria provided research
Natera, Inc. RCV000775052 SCV001460265 uncertain significance Familial hypercholesterolemia 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.